Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepatosplenic-Ty δ -cell lymphoma

Ava Diarra ¹ Benjamin Carpentier ² Romain Dubois ³ Stéphanie Poulain ⁴	
Leo Klapisz ⁵ Louis Terriou ¹ Meryem-Maud Farhat ¹	

¹Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), U1286 - INFINITE - Institute for Translational Research in Inflammation, Univ. Lille, Inserm, CHU Lille, Lille, France

²Hématologie Clinique, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France

³Department of Pathology, CHU Lille, Lille, France

⁴Service d'Hématologie Cellulaire, CANTHER, UMRS 9020 -UMR 1277 INSERM, Univ.Lille, INSERM, CHU Lille, Lille, France

⁵Department of Visceral Surgery, CHU Lille, Lille, France

Correspondence

Ava Diarra, Service de Médecine Interne, Hôpital Claude Huriez, CHU Lille, Rue Michel Polonovski, 59037 Lille Cedex, France. Email: ava.diarra@gmail.com

Funding information This research did not receive any specific funding

Abstract

Here we present the case of an hepato-splenic- $T\gamma\delta$ -cell lymphoma interestingly occurring in a non-immunocompromised patient, with profuse telangiectasias giving originally misleading orientation towards the diagnosis of B angiotropic lymphoma.

K E Y W O R D S angiotropic lymphoma, hepato splenic lymphoma, splenomegaly, telangiectasias

1 | CASE REPORT

A 50-year-old female with no significant past medical history presented with hectic fever, weight loss, asthenia, and abdominal pain 3 weeks before admission in our department. Closer examination revealed multiple telangiectasias located on the chest and upper back, with proximodistal extension (Figure 1). Physical examination displayed a voluminous hepatosplenomegaly. The biological analysis showed a hemophagocytic syndrome (HS) with inflammatory syndrome (CRP 41 mg/L). A small population of double-negative abnormal T-population CD2+ CD3+



FIGURE 1 Profuse telangiectasias on the patient's chest

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd.




FIGURE 2 (A) Spleen involvement with sheets of small neoplastic lymphoid cells involving cords and sinuses of spleen (hematoxylin and eosin [H&E] stain; original magnification ×600). (B) TiA1 immunohistochemical stain in spleen, highlighting the nonactivated cytotoxic phenotype of neoplastic T cells (original magnification ×600). (C) CD3 immunohistochemical stain in liver biopsy, highlighting the sinusoidal expansion by neoplastic T cells (original magnification ×600)




FIGURE 3 Perioperative splenectomy (9.8 * 7.9 inches)

CD4- CD8- CD5-CD56- CD16+ CD17+ accounting for 27.9% of total lymphocytes, presenting γδTCR was identified using flow cytometry. Medullar karyotype identified 44,X,-X,+8,add(10)(q26),-11,-21[6]/46,XX[14]. Plasma vascular endothelial growth factor (VEGF) level was significantly elevated (1140 pg/ml, normal value inferior to 500 pg/ml). A mutation of STAT5B T628S was identified by molecular biology. Computed tomography (CT) scan showed voluminous hepatosplenomegaly. Positron emission tomography-CT revealed diffuse hypermetabolism in the hepatosplenomegaly and regarding the osteomedullary area. The course was marked by worsening of the abdominal pain revealing a subcapsular intraparenchymal spleen rupture. The splenectomy associated with liver biopsy concluded hepatosplenic T CD4–/CD8– lymphoma stage IVBb (Figures 2 and 3).¹ Remarkably, the patient's global state improved after splenectomy. After two lines of chemotherapy, she received allogeneic stem cell transplantation from an unrelated donor.

ACKNOWLEDGMENTS None.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

AD, BC, LT, KL, and MMF managed the patients, and provided samples and clinical data. RD end SP performed anatomopathological and biological analysis. AD and MMF wrote the manuscript, which was approved by all the authors.

CONSENT

Written informed consent was obtained from the patient to publish this report in accordance with the Journal's patient consent policy.

ORCID

Ava Diarra Dittps://orcid.org/0000-0001-5468-0695

REFERENCE

 Pro B, Allen P, Behdad A. Hepatosplenic T-cell lymphoma: a rare but challenging entity. *Blood.* 2020;136(18):2018-2026. doi:10.1182/blood.2019004118

How to cite this article: Diarra A, Carpentier B, Dubois R, et al. Profuse telangiectasias in an immunocompetent patient misleading presentation revealing a hepatosplenic-T $\gamma\delta$ -cell lymphoma. *Clin Case Rep.* 2022;10:e05503. doi:10.1002/ccr3.5503